Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the transcript. The company discussed expected CAPEX for repurposing plants (Rs 20-30 crore for China Heliotropin plant, Rs 2-3 million for Italy plant), but these costs are expected to be borne by partners or internally funded. Finance costs have not increased due to additional borrowing; the increase is mainly due to foreign exchange impact. No new mentions or plans of equity or debt fundraising were disclosed during the call.

Any current/future capex/capital investment/strategic investment?

Repurposing of China Heliotropin plant with expected CAPEX of Rs 20-30 crores, to be borne by the partner (no cash outflow for Camlin Fine Sciences). Timeline not specified. Italy plant repurposing with anticipated CAPEX of Rs 2-3 million, expected to take 6-9 months. Revenues post-repurposing to start next year with EBITDA margins of 10-12%. Acquisition of Vitafor Invest NV, Belgium completed on June 11, 2024, enabling expansion into Northern Africa and East European markets with synergies in blends business. No specific CAPEX mentioned related to the Vitafor acquisition, but integration and

Future growth expectations in sales/revenue/volumes?

Blends business is expected to sustain robust growth with a healthy and substantial topline increase. Aroma segment's temporary weakness anticipated to be overcome in H2 with improved quality and quantity, especially in Vanillin products. Overall consolidated revenue remained stable despite Q1 softness, with demand recovering in Latin and South American markets. Pricing in Vanillin is seeing green shoots and some volume improvements are expected. Anti-dumping actions in US and Europe against Chinese manufacturers expected to positively impact Vanillin sales. The Vitafor acquisition o

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to stabilize performance, revenue, and margins amid improving economic cues. Robust growth in the blends business is anticipated to sustain through the year. Aroma segment weakness is expected to be overcome in the second half of FY25 with improved quality and quantity. EBITDA margins are targeted to reach double digits for the full year FY25. Topline growth is expected to be healthy and substantial, targeting around Rs. 2,000 crore revenue for the year. Operational efficiencies and some positive pricing trends, especially in Vanillin, are expected to support marg

Current/ Expected Orderbook/ Pending Orders?

Regarding the Lockheed Martin business, it is currently in the commissioning phase for their first commercial battery expected within this year. Commercial scaling and launch timelines are uncertain; thus, exact order book details and near-term business outlook are not specified. The company anticipates that significant revenue contributions from this business could materialize 2-3 years out once the battery is successfully commercialized. No specific order book figures or pending orders were disclosed for Lockheed Martin or other segments in the call. Hence, the current order book is not quan

IN US

Sale is live|00:00:00left today

Camlin Fine Sciences LtdQ2 FY24Chemicals & Petrochemicals

Camlin Fine Sciences Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138P/E: 1014.3Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Blends business is expected to sustain robust growth with a healthy and substantial topline increase.
→Aroma segment's temporary weakness anticipated to be overcome in H2 with improved quality and quantity, especially in Vanillin products.
→Overall consolidated revenue remained stable despite Q1 softness, with demand recovering in Latin and South American markets.
→Pricing in Vanillin is seeing green shoots and some volume improvements are expected.
→Anti-dumping actions in US and Europe against Chinese manufacturers expected to positively impact Vanillin sales.
→The Vitafor acquisition opens new geographic markets and product avenues, anticipated to scale up over coming quarters.
→Management targets achieving double-digit EBITDA margin and revenue growth around Rs. 2,000 crore for the year FY25.
→Recovery in demand expected in next quarters, with cautious optimism about pricing stabilization and operational efficiencies improving margins.

Margin guidance

Category 3

→The company expects to stabilize performance, revenue, and margins amid improving economic cues.
→Robust growth in the blends business is anticipated to sustain through the year.
→Aroma segment weakness is expected to be overcome in the second half of FY25 with improved quality and quantity.
→EBITDA margins are targeted to reach double digits for the full year FY25.
→Topline growth is expected to be healthy and substantial, targeting around Rs. 2,000 crore revenue for the year.
→Operational efficiencies and some positive pricing trends, especially in Vanillin, are expected to support margin improvement.
→Repurposing of European and Italy facilities is underway, with new revenue streams expected next year, aiming at 10-12% EBITDA margins from these plants in the future.
→Lockheed Martin related business is expected to potentially yield substantial numbers 2-3 years out, though current contributions and timelines are uncertain.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the transcript.
→The company discussed expected CAPEX for repurposing plants (Rs 20-30 crore for China Heliotropin plant, Rs 2-3 million for Italy plant), but these costs are expected to be borne by partners or internally funded.
→Finance costs have not increased due to additional borrowing; the increase is mainly due to foreign exchange impact.
→No new mentions or plans of equity or debt fundraising were disclosed during the call.

Order book

→Regarding the Lockheed Martin business, it is currently in the commissioning phase for their first commercial battery expected within this year.
→Commercial scaling and launch timelines are uncertain; thus, exact order book details and near-term business outlook are not specified.
→The company anticipates that significant revenue contributions from this business could materialize 2-3 years out once the battery is successfully commercialized.
→No specific order book figures or pending orders were disclosed for Lockheed Martin or other segments in the call.
→Hence, the current order book is not quantifiable at this time, and the company considers Lockheed Martin business still in the pipeline phase.

Capex plans

Yes

→Repurposing of China Heliotropin plant with expected CAPEX of Rs 20-30 crores, to be borne by the partner (no cash outflow for Camlin Fine Sciences). Timeline not specified.
→Italy plant repurposing with anticipated CAPEX of Rs 2-3 million, expected to take 6-9 months. Revenues post-repurposing to start next year with EBITDA margins of 10-12%.
→Acquisition of Vitafor Invest NV, Belgium completed on June 11, 2024, enabling expansion into Northern Africa and East European markets with synergies in blends business.
→No specific CAPEX mentioned related to the Vitafor acquisition, but integration and scaling up initiatives ongoing.
→No other immediate CAPEX or strategic investment details disclosed in the call.

How does Camlin Fine Sciences Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Camlin Fine Sciences Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Camlin Fine Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio